Kiley T D
Science. 1992 Aug 14;257(5072):915-8. doi: 10.1126/science.1502558.
The proposal by the National Institutes of Health (NIH) to patent products resulting merely from sequencing the human genome is a mistake: at worst, it is wrong in patent law; at best, it relies on deficiencies in law concerning what is "useful" as a requirement for patents. The proposal is symptomatic of a problem besieging biotechnology--attempts to control the raw material of scientific experimentation before research has determined the practical value of such material--that needs curing on many fronts. Corrective measures are proposed for adoption by the Executive branch, the Congress, and the courts.
美国国立卫生研究院（NIH）提出仅对人类基因组测序产生的产品申请专利是一个错误：往最坏处说，这在专利法上是错误的；往最好处说，它依赖于专利法中关于什么是“有用的”这一要求方面的缺陷。该提议是困扰生物技术领域的一个问题的症状——即在研究确定此类材料的实际价值之前试图控制科学实验的原材料——这需要在许多方面加以解决。建议行政部门、国会和法院采取纠正措施。
